Skip to main content
common_image

Metabolic

About 425 million adult people in the world are living with diabetes, with Type 2 diabetes accounting for 90 percent of all cases1. This number is projected to increase to 629 million people by 20451. Type 2 diabetes is a chronic, progressive condition and long-term complications include stroke, heart attack and cardiovascular death as well as diabetic kidney disease, retinopathy, arm and leg amputations and autonomic neuropathy. In addition to the now marketed products from our own R&D, we are also focused on cardiometabolic indications with a high unmet medical need.

1Diabetes Atlas 8th edition 2017, International Diabetes Federation. http://www.diabetesatlas.org (link is external) (accessed Apr 2018)

Learn More
JardianceJardianceJardiance

Jardiance®

Treatment of adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control and to reduce the risk of cardiovascular death in patients with established cardiovascular disease.
Learn More
Learn More
Trajenta

Trajenta®

Treatment of adults with type 2 diabetes mellitus to improve glycaemic control in conjunction with diet and exercise, as monotherapy or as add on to metformin, sulphonylureas, thiazolidinediones, insulin (with or without metformin and/or pioglitazone and/or sulphonylureas or metformin plus SGLT2 inhibitors.
Learn More

Respiratory

Boehringer Ingelheim has over 90 years of heritage in respiratory disease. Since 1921 we have emerged as a leader in this disease area, having launched several treatments in a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer. Our focus is on improving the quality of life of patients suffering from debilitating respiratory diseases and enabling them to maintain a more independent life.

Cardiovascular

Cardiovascular disease, including heart disease and stroke, is a major global health concern and the leading cause of death and disability worldwide1. At Boehringer Ingelheim we address unmet medical need by providing innovative treatments that improve the care of patients suffering from a range of cardiovascular conditions including irregular heartbeat (atrial fibrillation), stroke, blood clots in deep veins or lungs (deep vein thrombosis or pulmonary embolism), high blood pressure (hypertension) or heart attack (myocardial infarction).

1Vilahur G et al. Eur Heart J Suppl 2014; 16(Suppl_A): A7-A11.

Learn More
Actilyse

Actilyse®

Actilyse® (alteplase or recombinant tissue plasminogen activator, rt-PA), is the only recommended intravenous thrombolytic for the treatment of an acute ischaemic stroke.
Learn More
Learn More
Telmisartan (Micardis®)

Micardis

Is a true once daily Angiotensin II Inhibitor. It is used to treat essential hypertension (high blood pressure) in adults. And clinically proven to reduce cardiovascular events (i.e. heart attack or stroke) in adults who are at risk or have had a stroke or have high risk diabetes.
Learn More